studies

metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), nivolumab plus ipilimumab vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 0.79 [0.65; 0.96] CheckMate 9LA, 2021 0.69 [0.55; 0.87] 0.75[0.64; 0.87]CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 9LA, 202120%1,512moderatenot evaluable deaths (OS) (extension)detailed resultsCheckMate 9LA, 2021 0.66 [0.55; 0.80] 0.66[0.55; 0.80]CheckMate 9LA, 202110%719NAnot evaluable PFS (extension)detailed resultsCheckMate 9LA, 2021 0.68 [0.57; 0.82] 0.68[0.57; 0.82]CheckMate 9LA, 202110%719NAnot evaluable progression or deaths (PFS)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 0.82 [0.69; 0.97] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.58 [0.41; 0.82] CheckMate 9LA, 2021 0.70 [0.57; 0.86] 0.72[0.61; 0.86]CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021344%1,811moderatenot evaluable objective responses (ORR)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 1.31 [0.97; 1.76] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2.26 [1.39; 3.66] CheckMate 9LA, 2021 1.80 [1.31; 2.48] 1.68[1.24; 2.26]CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021353%1,811moderatenot evaluable STRAE (any grade)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 1.96 [1.36; 2.83] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2.67 [1.51; 4.74] CheckMate 9LA, 2021 1.94 [1.36; 2.76] 2.05[1.63; 2.59]CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 202130%1,779moderatenot evaluable STRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 1.98 [1.32; 2.98] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2.19 [1.14; 4.20] CheckMate 9LA, 2021 1.95 [1.33; 2.84] 2.00[1.55; 2.58]CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 202130%1,779moderatenot evaluable TRAE (any grade)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 0.66 [0.46; 0.94] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.28 [0.71; 2.30] CheckMate 9LA, 2021 1.55 [0.94; 2.55] 1.06[0.60; 1.89]CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021377%1,779moderatenot evaluable TRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 0.96 [0.72; 1.29] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.02 [0.64; 1.65] CheckMate 9LA, 2021 1.44 [1.06; 1.94] 1.14[0.87; 1.49]CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021347%1,779moderatenot evaluable TRAE leading to death (grade 5)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 0.99 [0.28; 3.45] CheckMate 9LA, 2021 1.14 [0.38; 3.43] 1.07[0.47; 2.45]CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 9LA, 202120%1,485moderatenot evaluable TRAE leading to discontinuation (any grade)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 3.13 [1.95; 5.03] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 3.49 [1.78; 6.83] CheckMate 9LA, 2021 3.18 [1.94; 5.19] 3.22[2.38; 4.36]CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 202130%1,779moderatenot evaluable TRAE leading to discontinuation (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 5.13 [2.63; 10.00] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 2.90 [1.32; 6.37] CheckMate 9LA, 2021 3.48 [2.00; 6.05] 3.77[2.59; 5.49]CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 202130%1,779moderatenot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsCheckMate 9LA, 2021 7.88 [0.41; 149.53] 7.88[0.41; 149.53]CheckMate 9LA, 202110%707NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 0.11 [0.04; 0.28] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.26 [0.07; 0.92] CheckMate 9LA, 2021 0.37 [0.22; 0.63] 0.23[0.10; 0.52]CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021360%1,779moderatenot evaluable Asthenia TRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 1.24 [0.33; 4.65] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.18 [0.23; 5.95] CheckMate 9LA, 2021 0.36 [0.09; 1.37] 0.78[0.34; 1.75]CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 202131%1,779moderatenot evaluable Colitis TRAE (grade 3-4)detailed resultsCheckMate 9LA, 2021 9.87 [0.54; 181.39] 9.87[0.54; 181.39]CheckMate 9LA, 202110%707NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 0.99 [0.02; 50.01] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.59 [0.02; 17.65] CheckMate 9LA, 2021 0.97 [0.02; 49.27] 0.80[0.09; 6.87]CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 202130%1,779moderatenot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 0.99 [0.25; 3.99] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.29 [0.03; 2.62] CheckMate 9LA, 2021 0.97 [0.24; 3.93] 0.80[0.33; 1.97]CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 202130%1,779moderatenot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 3.00 [0.60; 14.96] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.78 [0.29; 10.84] CheckMate 9LA, 2021 7.06 [1.59; 31.30] 3.66[1.44; 9.30]CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 202130%1,779moderatenot evaluable Fatigue TRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 2.00 [0.60; 6.70] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.29 [0.03; 2.62] CheckMate 9LA, 2021 3.97 [0.84; 18.81] 1.64[0.47; 5.72]CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021345%1,779moderatenot evaluable Febrile neutropenia TRAE (grade 3-4)detailed resultsCheckMate 9LA, 2021 1.38 [0.60; 3.15] 1.38[0.60; 3.15]CheckMate 9LA, 202110%707NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.18 [0.02; 59.79] CheckMate 9LA, 2021 1.95 [0.07; 58.39] 1.57[0.12; 20.54]CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 202120%1,001moderatenot evaluable Increased ALT TRAE (grade 3-4)detailed resultsCheckMate 9LA, 2021 2.46 [0.47; 12.75] 2.46[0.47; 12.75]CheckMate 9LA, 202110%707NAnot evaluable Increased lipase level TRAE (grade 3-4)detailed resultsCheckMate 9LA, 2021 7.55 [2.24; 25.47] 7.55[2.24; 25.47]CheckMate 9LA, 202110%707NAnot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsCheckMate 9LA, 2021 4.93 [0.57; 42.41] 4.93[0.57; 42.41]CheckMate 9LA, 202110%707NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 0.28 [0.06; 1.35] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 1.18 [0.16; 8.49] CheckMate 9LA, 2021 1.63 [0.39; 6.89] 0.81[0.26; 2.48]CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021329%1,779moderatenot evaluable Neutropenia TRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 0.01 [0.00; 0.23] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.03 [0.00; 0.46] CheckMate 9LA, 2021 0.71 [0.41; 1.24] 0.08[0.00; 1.53]CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021383%1,779moderatenot evaluable Pruritus TRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 3.97 [0.18; 88.42] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 4.77 [0.21; 106.62] CheckMate 9LA, 2021 5.89 [0.29; 118.02] 4.84[0.82; 28.43]CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 202130%1,779moderatenot evaluable Rash TRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 18.21 [1.05; 315.26] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 7.20 [0.36; 145.12] CheckMate 9LA, 2021 11.88 [0.66; 213.53] 11.78[2.19; 63.31]CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 202130%1,779moderatenot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsCheckMate 9LA, 2021 1.09 [0.44; 2.70] 1.09[0.44; 2.70]CheckMate 9LA, 202110%707NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsCheckMate 227 (NI vs C ; PDL1>1%), 2018 0.10 [0.01; 0.76] CheckMate 227 (NI vs C ; TMB >10 Mb), 2018 0.19 [0.02; 1.60] CheckMate 9LA, 2021 1.17 [0.35; 3.88] 0.34[0.07; 1.74]CheckMate 227 (NI vs C ; PDL1>1%), 2018, CheckMate 227 (NI vs C ; TMB >10 Mb), 2018, CheckMate 9LA, 2021361%1,779moderatenot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:24 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 196,36,228,174,171,173,307,165,163,176,308,164,166,220 - treatments: 416,864